サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1544086

皮膚糸状菌性爪真菌症治療の世界市場

Dermatophytic Onychomycosis Treatment

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
皮膚糸状菌性爪真菌症治療の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

皮膚糸状菌性爪真菌症治療の世界市場は2030年までに106億米ドルに達する見込み

2023年に75億米ドルと推定される皮膚糸状菌性爪真菌症治療の世界市場は、2023年から2030年にかけてCAGR 5.1%で成長し、2030年には106億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである局所療法は、CAGR 6.1%を記録し、分析期間終了時には71億米ドルに達すると予測されます。全身療法分野の成長率は、分析期間中CAGR 3.3％と推定されます。

米国市場は20億米ドルと推定、中国はCAGR 4.8％で成長予測

米国の皮膚糸状菌性爪真菌症治療市場は2023年に20億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.0％と3.9％と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の皮膚糸状菌性爪真菌症治療市場- 主要動向と促進要因まとめ

皮膚糸状菌性爪真菌症とは何か？

皮膚糸状菌性爪甲真菌症は、一般的に爪真菌と呼ばれ、主に足の爪を侵す真菌感染症です。皮膚糸状菌は、暖かく湿った環境で増殖する真菌の一種であり、足の爪は靴の中に入っていることが多いため、格好の標的となります。この症状は爪の肥厚、変色、割れを特徴とし、かなりの痛みを伴うことがあり、しばしば大きな不快感や恥ずかしさにつながります。爪甲真菌症の有病率は、特に高齢者、糖尿病患者、免疫力が低下している人の間で高く、これらの人は血行が悪く爪の成長が低下しているため、リスクが高くなります。治療は、美容上の理由だけでなく、他の爪への感染の拡大や、より深刻な他の個人への感染を防ぐためにも非常に重要です。この状態を効果的に管理するには、薬理学的治療と、場合によっては外科的介入を組み合わせる必要があります。

爪真菌症に対する現在の治療はどのように進化しているか？

皮膚糸状菌性爪甲真菌症の治療法は、過去10年間で大きく進化し、より効果的で侵襲の少ない選択肢へとシフトしています。従来は、抗真菌薬の内服による治療が行われてきたが、抗真菌薬は効果的であるが、肝障害や皮疹などの重篤な副作用を起こすことがあり、血液検査による定期的なモニタリングが必要でした。外用治療薬はより安全であるが、一般的に効果は低く、特に重症の感染症に有効です。最近の動向により、より効率的な外用薬、副作用の少ない改良された内服薬、レーザーや光線力学的療法のような新しい治療法が開発されています。これらの新しい治療法は、より直接的に真菌をターゲットとするため、治療期間を短縮し、副作用を最小限に抑えながら有効性を向上させる可能性があります。さらに、より刺激の少ない治療法を求める患者にとって魅力的な、自然療法や代替療法の使用に対する関心も高まっています。

治療成績の向上においてテクノロジーが果たす役割とは？

技術の革新は、皮膚糸状菌性爪甲真菌症の診断と治療の改善に極めて重要な役割を果たしています。光干渉断層計のような高度な画像診断技術により、感染範囲がより正確に可視化され、より的を絞った治療が可能になりました。さらに、レーザー治療の開発により、爪真菌症管理に新たな局面がもたらされ、全身治療に伴う副作用のない、迅速かつ安全で繰り返し可能な治療オプションが提供されるようになった。これらのレーザーは爪を貫通し、周囲の爪や皮膚を傷つけることなく、熱で真菌を破壊することで効果を発揮します。さらに、外用治療薬の送達メカニズムに関する継続的な研究により、その有効性が向上しています。例えば、爪の硬い外面に浸透しやすい新しい形態の薬剤が現在開発されています。このような技術の進歩は、患者の治療成績を向上させるだけでなく、治療プロトコルの全体的な効率も高めています。

皮膚糸状菌性爪真菌症治療市場の成長の原動力は？

皮膚糸状菌性爪真菌症治療市場の成長は、免疫力の低下や血液循環の悪化により真菌感染症にかかりやすくなる世界の高齢化など、いくつかの要因によってもたらされます。認知度の向上や診断技術の向上も、治療率の向上に寄与しています。さらに、ジム、プール、スパなどの共用スペースにさらされる機会が増えるライフスタイルの変化が、真菌感染症の発生率の上昇につながっています。より新しく、より効果的で、より安全な治療法の開発と、美的外観に対する嗜好の高まりが、高度な爪真菌症治療に対する需要を促進しています。ヘルスケアプロバイダーがより効率的で患者に優しい治療法を模索し続ける中、薬理学的および技術的な領域における継続的な革新と改善がさらなる成長の原動力となり、市場は拡大すると予想されます。

調査対象企業の例（全44件）

  • Allergan PLC
  • Galderma SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Moberg Pharma AB
  • NovaBiotics Ltd
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Valeant Pharmaceuticals International, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11505

Global Dermatophytic Onychomycosis Treatment Market to Reach US$10.6 Billion by 2030

The global market for Dermatophytic Onychomycosis Treatment estimated at US$7.5 Billion in the year 2023, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Topical Therapy, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Systemic Therapy segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 4.8% CAGR

The Dermatophytic Onychomycosis Treatment market in the U.S. is estimated at US$2.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.0% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Dermatophytic Onychomycosis Treatment Market - Key Trends and Drivers Summarized

What Is Dermatophytic Onychomycosis and Why Is It a Concern?

Dermatophytic onychomycosis, commonly referred to as toenail fungus, involves a fungal infection that affects the nails, primarily the toenails. It is caused by dermatophytes, a type of fungus that thrives in warm, moist environments, making toenails a prime target due to their frequent enclosure in shoes. This condition is characterized by thickening, discoloration, and splitting of the nail, and can be quite painful, often leading to significant discomfort and embarrassment. The prevalence of onychomycosis is particularly high among the elderly, diabetic, and those with compromised immune systems, who are at greater risk due to poorer circulation and reduced nail growth. Treatment is crucial not only for cosmetic reasons but also to prevent the spread of the infection to other nails or, more seriously, to other individuals. Effective management of the condition requires a combination of pharmacological treatments and, in some cases, surgical intervention.

How Are Current Treatments Evolving in the Fight Against Onychomycosis?

The treatment landscape for dermatophytic onychomycosis has evolved significantly over the past decade, with a shift towards more effective and less invasive options. Traditionally, the approach has included oral antifungal medications, which are effective but can have serious side effects, such as liver damage or skin rashes, necessitating regular monitoring with blood tests. Topical treatments are safer but generally less effective, especially for more severe infections. Recent advancements have led to the development of more efficient topical solutions, improved oral medications with fewer side effects, and novel treatment modalities like laser and photodynamic therapy. These newer methods target the fungus more directly, potentially reducing treatment duration and improving efficacy with minimal side effects. Additionally, there is a growing interest in the use of natural and alternative remedies, which appeal to patients seeking less harsh treatment options.

What Role Does Technology Play in Enhancing Treatment Outcomes?

Innovations in technology are playing a pivotal role in improving the diagnosis and treatment of dermatophytic onychomycosis. Advanced imaging techniques, such as optical coherence tomography, allow for more accurate visualization of the infection extent, facilitating more targeted treatments. Additionally, the development of laser therapy has introduced a new dimension to onychomycosis management, offering a quick, safe, and repeatable treatment option without the side effects associated with systemic therapies. These lasers work by penetrating the nail and destroying the fungi with heat without damaging the surrounding nail or skin. Moreover, ongoing research into the delivery mechanisms of topical treatments is enhancing their effectiveness; for example, new forms of medication that can better penetrate the nail's hard exterior are currently being developed. This technological progress not only improves patient outcomes but also enhances the overall efficiency of treatment protocols.

What Drives the Growing Market for Dermatophytic Onychomycosis Treatment?

The growth in the dermatophytic onychomycosis treatment market is driven by several factors, including an aging global population, which is more susceptible to fungal infections due to decreased immunity and poor blood circulation. Increased awareness and better diagnostic techniques are also contributing to higher treatment rates. Furthermore, lifestyle changes that increase exposure to communal areas such as gyms, pools, and spas are leading to a higher incidence of fungal infections. The development of newer, more effective, and safer treatments, along with a rising preference for aesthetic appearance, is fueling demand for advanced onychomycosis treatments. As healthcare providers continue to seek more efficient and patient-friendly treatment options, the market is expected to expand, with continued innovations and improvements in both pharmacological and technological domains driving growth further.

Select Competitors (Total 44 Featured) -

  • Allergan PLC
  • Galderma SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Moberg Pharma AB
  • NovaBiotics Ltd
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Valeant Pharmaceuticals International, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Dermatophytic Onychomycosis Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Diabetes Bolsters Demand for Onychomycosis Treatment
    • Advances in Antifungal Therapies Propel Market Growth
    • Increased Awareness of Foot Health Drives Adoption of Treatments
    • Growing Elderly Population Sustains Demand for Effective Onychomycosis Solutions
    • Expansion of Over-the-Counter Antifungal Products Generates Greater Consumer Access
    • The Role of Podiatrists and Dermatologists in Driving Treatment Adoption
    • Telemedicine and Online Consultations Expand Patient Reach
    • Growing Demand for Natural and Alternative Treatment Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Dermatophytic Onychomycosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Systemic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Systemic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Systemic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Topical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Topical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Topical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Device-based Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Device-based Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Device-based Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Dermatology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Dermatology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Dermatology Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Dermatophytic Onychomycosis Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Dermatophytic Onychomycosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Dermatophytic Onychomycosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Dermatophytic Onychomycosis Treatment by Segment - Topical Therapy, Systemic Therapy and Device-based Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Dermatophytic Onychomycosis Treatment by Segment - Percentage Breakdown of Value Sales for Topical Therapy, Systemic Therapy and Device-based Therapy for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Dermatophytic Onychomycosis Treatment by End-Use - Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Dermatophytic Onychomycosis Treatment by End-Use - Percentage Breakdown of Value Sales for Dermatology Clinics, Hospitals, Retail Pharmacies and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION